• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    5/13/24 12:31:04 PM ET
    $APDN
    $BNTC
    $CCLD
    $CHRO
    Other Consumer Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APDN alert in real time by email

    Gainers

    • CareCloud (NASDAQ:CCLD) stock moved upwards by 80.5% to $2.27 during Monday's regular session. The company's market cap stands at $36.6 million.
    • Novavax (NASDAQ:NVAX) stock rose 42.17% to $12.62. The market value of their outstanding shares is at $1.7 billion. The company's, Q1 earnings came out yesterday.
    • Macrogenics (NASDAQ:MGNX) stock rose 27.79% to $4.23. The market value of their outstanding shares is at $264.6 million. As per the news, the Q1 earnings report came out 2 days ago.
    • Chromocell Therapeutics (AMEX:CHRO) shares moved upwards by 25.68% to $2.3. The market value of their outstanding shares is at $13.5 million.
    • Omega Therapeutics (NASDAQ:OMGA) shares moved upwards by 24.01% to $2.43. The market value of their outstanding shares is at $134.0 million.
    • Titan Pharma (NASDAQ:TTNP) shares increased by 21.74% to $8.4. The market value of their outstanding shares is at $7.6 million.

    Losers

    • TransCode Therapeutics (NASDAQ:RNAZ) shares declined by 40.1% to $0.84 during Monday's regular session. The company's market cap stands at $5.1 million.
    • Applied DNA Sciences (NASDAQ:APDN) stock fell 22.03% to $2.69. The market value of their outstanding shares is at $2.3 million. The company's, Q2 earnings came out yesterday.
    • Heart Test Laboratories (NASDAQ:HSCS) stock declined by 19.66% to $0.07. The company's market cap stands at $4.6 million.
    • Benitec Biopharma (NASDAQ:BNTC) shares decreased by 16.76% to $7.7. The market value of their outstanding shares is at $65.4 million. As per the press release, Q3 earnings came out today.
    • Oragenics (AMEX:OGEN) stock declined by 16.12% to $1.54. The market value of their outstanding shares is at $6.9 million.
    • Fortrea Holdings (NASDAQ:FTRE) shares declined by 15.78% to $27.82. The company's market cap stands at $2.4 billion. The company's, Q1 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APDN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APDN
    $BNTC
    $CCLD
    $CHRO

    CompanyDatePrice TargetRatingAnalyst
    Fortrea Holdings Inc.
    $FTRE
    1/8/2026$22.00Hold → Buy
    Truist
    Fortrea Holdings Inc.
    $FTRE
    1/6/2026$25.00In-line → Outperform
    Evercore ISI
    Fortrea Holdings Inc.
    $FTRE
    12/15/2025$15.00Underweight → Equal Weight
    Barclays
    Fortrea Holdings Inc.
    $FTRE
    12/11/2025$21.00Neutral → Buy
    Citigroup
    Novavax Inc.
    $NVAX
    10/24/2025$18.00Overweight
    Cantor Fitzgerald
    MacroGenics Inc.
    $MGNX
    9/17/2025$3.00Overweight
    Barclays
    Novavax Inc.
    $NVAX
    8/28/2025$10.00Buy
    H.C. Wainwright
    Novavax Inc.
    $NVAX
    8/20/2025$7.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $APDN
    $BNTC
    $CCLD
    $CHRO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $APDN
    $BNTC
    $CCLD
    $CHRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

    TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.BOSTON, March 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. ("Unleash"). TransCode obtained the rights to develop three Unleash drug candidates, UIO-524, UIO-525 and UIO-526, which includes a license of all in-licensed rights held by

    3/3/26 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MacroGenics to Participate in Upcoming Investor Conferences

    ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management team will participate in the following investor conferences in March: TD Cowen 46th Annual Health Care Conference (Boston, MA). MacroGenics' President and CEO, Eric Risser, will participate in a hybrid presentation and fireside chat on Tuesday, March 3, at 3:10 pm ET. MacroGenics' management will also participate in one-on-one meetings.Leerink Partners 2026 Global Healthcare Conference (Miami, FL). Mr. Risser will participate in a fireside chat on

    2/26/26 5:30:00 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novavax to Participate in Upcoming Investor Conferences

    GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), today announced that it will participate in the following upcoming investor conferences:TD Cowen 46th Annual Health Care Conference:Fireside ChatDate:Tuesday, March 3, 2026Time:2:30 p.m. Eastern Time (ET)Location:Boston, MALeerink Partners 2026 Global Healthcare Conference:Fireside ChatDate:Tuesday, March 10, 2026Time:3:40 p.m. ETLocation:Miami Beach, FLJefferies Biotech on the Beach Summit:Investor MeetingsDate:Wednesday, March 11, 2026Location:Miami Beach, FLA webcast of the fireside chats will be available through the Events and Presentations page of the Company's website at ir.novavax.com. A replay of each webc

    2/26/26 4:30:00 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APDN
    $BNTC
    $CCLD
    $CHRO
    SEC Filings

    View All

    SEC Form DEFA14A filed by TransCode Therapeutics Inc.

    DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

    3/3/26 4:06:34 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    3/3/26 4:05:39 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MacroGenics Inc. filed SEC Form 8-K: Other Events

    8-K - MACROGENICS INC (0001125345) (Filer)

    3/2/26 4:15:28 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $BNTC
    $CCLD
    $CHRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Suvretta Capital Management, Llc bought $1,903,133 worth of shares (144,223 units at $13.20) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/29/25 7:31:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $538,972 worth of shares (46,141 units at $11.68) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/22/25 7:45:03 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $19,999,994 worth of shares (1,481,481 units at $13.50) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    11/10/25 9:51:33 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $BNTC
    $CCLD
    $CHRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Jacobs John C converted options into 150,167 shares and covered exercise/tax liability with 69,288 shares, increasing direct ownership by 98% to 225,680 units (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    3/5/26 6:03:17 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP, CFO and Treasurer Kelly James Patrick converted options into 43,167 shares and covered exercise/tax liability with 20,850 shares, increasing direct ownership by 22% to 124,280 units (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    3/5/26 6:04:04 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP, Chief Strategy Officer O'Hara Elaine converted options into 56,334 shares and covered exercise/tax liability with 22,429 shares, increasing direct ownership by 34% to 134,642 units (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    3/5/26 6:02:23 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APDN
    $BNTC
    $CCLD
    $CHRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fortrea upgraded by Truist with a new price target

    Truist upgraded Fortrea from Hold to Buy and set a new price target of $22.00

    1/8/26 8:10:34 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Fortrea from In-line to Outperform and set a new price target of $25.00

    1/6/26 8:26:05 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Barclays with a new price target

    Barclays upgraded Fortrea from Underweight to Equal Weight and set a new price target of $15.00

    12/15/25 9:05:06 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $APDN
    $BNTC
    $CCLD
    $CHRO
    Leadership Updates

    Live Leadership Updates

    View All

    CareCloud Appoints Chief Strategy Officer to Lead Enterprise AI Platform as Company Enters 2026 as Its Defining AI Year

    Strategic leadership alignment positions CareCloud to scale execution, expand margins, and accelerate AI-driven innovation across ambulatory and hospital markets SOMERSET, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (NASDAQ:CCLD, CCLDO)), ("CareCloud" or the "Company") a leader in healthcare technology and AI-powered solutions, today announced leadership promotions designed to align the organization for its next phase of growth and to position 2026 as a defining year for enterprise AI innovation across the Company's platform. Effective January 1, 2026, A. Hadi Chaudhry will serve as Chief Strategy Officer, leading CareCloud's enterprise AI vision, platform innovation, and com

    12/29/25 8:00:00 AM ET
    $CCLD
    Computer Software: Prepackaged Software
    Technology

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

    Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

    11/17/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $BNTC
    $CCLD
    $CHRO
    Financials

    Live finance-specific insights

    View All

    Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&

    2/26/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

    Revenue and Adjusted EBITDA results delivered in line with stated full-year targetsFull‑year cost savings exceeded previously communicated targets Highlights: Revenues of $660.5 million for the fourth quarter and $2,723.4 million for the full yearFourth-quarter book-to-bill ratio of 1.14x, resulting in 1.02x book-to-bill for the trailing 12 monthsGAAP net loss of $(32.5) million, or $(0.35) per diluted share for the fourth quarter; $(986.2) million, or $(10.81) per diluted share for the full yearAdjusted EBITDA of $54.0 million for the fourth quarter and $189.9 million for the full yearAdjusted net income of $9.2 million, or $0.09 per diluted share for the fourth quarter; $40.4 million, or

    2/26/26 6:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:Conference call details:Date:February 26, 2026Time:8:30 a.m. ETURL to register phone:Register HereDial-in number:(888) 880-3330 (U.S.) or(+1) (646) 357-8766 (International)Webcast:ir.novavax.com/eventsParticipants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can als

    2/19/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APDN
    $BNTC
    $CCLD
    $CHRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    12/6/24 1:47:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by MacroGenics Inc.

    SC 13G - MACROGENICS INC (0001125345) (Subject)

    11/20/24 10:44:27 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Benitec Biopharma Inc.

    SC 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)

    11/18/24 4:36:00 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care